Foster Victor Wealth Advisors LLC Has $15.17 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Foster Victor Wealth Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 598,475 shares of the biopharmaceutical company's stock after purchasing an additional 34,440 shares during the period. Pfizer makes up 1.2% of Foster Victor Wealth Advisors LLC's portfolio, making the stock its 27th biggest position. Foster Victor Wealth Advisors LLC's holdings in Pfizer were worth $15,165,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Lipe & Dalton raised its position in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares in the last quarter. Beam Wealth Advisors Inc. raised its position in Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock worth $728,000 after purchasing an additional 401 shares in the last quarter. Providence Capital Advisors LLC grew its stake in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after buying an additional 409 shares during the last quarter. Donaldson Capital Management LLC grew its stake in Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after buying an additional 410 shares during the last quarter. Finally, Noesis Capital Mangement Corp grew its stake in Pfizer by 2.6% during the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock worth $434,000 after buying an additional 413 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Trading Down 1.3%

PFE stock traded down $0.33 during midday trading on Friday, reaching $24.51. The company's stock had a trading volume of 46,354,360 shares, compared to its average volume of 41,209,115. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market cap of $139.35 billion, a PE ratio of 17.38, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business's 50-day simple moving average is $23.06 and its 200-day simple moving average is $24.95.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. The business's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were paid a $0.43 dividend. The ex-dividend date was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.02%. Pfizer's payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.